* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Sartorius AG's PEG Ratio or its related term are showing as below:
XTER:SRT3'
s PEG Ratio Range Over the Past 10 Years
Min: 0.65 Med: 3.09 Max: 11.08
Current: 2
During the past 13 years, Sartorius AG's highest PEG Ratio was 11.08. The lowest was 0.65. And the median was 3.09.
XTER:SRT3's PEG Ratio is ranked worse than 52.61% of 249
companies
in the Medical Devices & Instruments industry
Industry Median: 1.8
vs XTER:SRT3: 2.00
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Sartorius AG PEG Ratio Historical Data
The historical data trend for Sartorius AG's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sartorius AG's PEG Ratio
For the Medical Instruments & Supplies subindustry, Sartorius AG's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius AG's PEG Ratio Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Sartorius AG's PEG Ratio falls into.
Sartorius AG PEG Ratio Calculation
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio.
The ratio we use is the 5-Year EBITDA growth rate.
Sartorius AG's PEG Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Sartorius AG (XTER:SRT3) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Sartorius AG PEG Ratio Related Terms
Thank you for viewing the detailed overview of Sartorius AG's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XTER:SRT3 has been successfully added to your 